Vaccines, Blood & Biologics

IMLYGIC (talimogene laherparepvec)

STN:  125518
Proper Name: talimogene laherparepvec
Tradename: IMLYGIC
Manufacturer: Amgen Inc.
Indication:

  • Indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery.

 

Page Last Updated: 03/01/2018
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English